Yuliya Kolyako

Yuliya Kolyako


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Cells
Verified
Journal Article
Open access
PDF file
EBEkaterina Bayurova
Ekaterina Bayurova
AZAlla Zhitkevich
Alla Zhitkevich
DADaria Avdoshina
Daria Avdoshina
NKNatalya Kupriyanova
Natalya Kupriyanova
YKYuliya Kolyako
Yuliya Kolyako
IGIlya Gordeychuk
Ilya Gordeychuk
Common marmosets (Callithrix jacchus; CMs) are small New World primates widely used in biomedical research. Early stages of such research often include in vitro experiments which require standardized and well-characterized CM cell cultures derived from different tissues. Despite the long history of laboratory work with CMs and high translational potential of such studies, the number of available standardized, well-defined, stable, and validated CM cell lines is still small. While primary cells and immortalized cell lines are mostly used for the studies of infectious diseases, biochemical research, and targeted gene therapy, the main current applications of CM embryonic stem cells and induced pluripotent stem cells are regenerative medicine, stem cell research, generation of transgenic CMs, transplantology, cell therapy, reproductive physiology, oncology, and neurodegenerative diseases. In this review we summarize the data on the main advantages, drawbacks and research applications of CM cell lines published to date including primary cells, immortalized cell lines, lymphoblastoid cell lines, embryonic stem cells, and induced pluripotent stem cells.

1 November 2025 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
YKYuliya Kolyako
Yuliya Kolyako
AZAlla S. Zhitkevich
Alla S. Zhitkevich
DADaria V. Avdoshina
Daria V. Avdoshina
DTDaria Y. Tanygina
Daria Y. Tanygina
VAVasiliy D. Apolokhov
Vasiliy D. Apolokhov
IGIlya V. Gordeychuk
Ilya V. Gordeychuk
Hepatitis B virus (Orthohepadnavirus hominoidei, HBV) is a hepatotropic virus from the Hepadnaviridae family and the causative agent of both acute and chronic hepatitis B (CHB). The possible outcomes of CHB include liver cirrhosis and hepatocellular carcinoma (HCC) that pose a significant burden on the healthcare systems worldwide. In the nuclei of infected hepatocytes of patients with CHB, the HBV genome persists as a pool of covalently closed circular DNA (cccDNA) molecules. Current therapeutic strategies cannot directly target cccDNA. Instead, the available treatments focus on long-term suppression of viral replication and require lifelong administration. Development and evaluation of novel antiviral agents capable of achieving complete HBV eradication require relevant in vivo and in vitro models of HBV infection. Among the available animal models, the following categories are distinguished: (i) animals naturally susceptible to HBV; (ii) surrogate models using animal species susceptible to the related hepadnaviruses; (iii) non-susceptible animals receiving HBV genome via recombinant viral vectors; (iv) models utilizing human hepatocyte xenografts. Among the available in vitro models, primary human and northern treeshrew (Tupaia belangeri) hepatocytes fully support the HBV replication cycle, but they rapidly lose susceptibility to the virus in cell culture. In turn, unmodified human hepatoma cell lines are not susceptible to HBV but can support viral replication after transfection with the viral genome. This review discusses key characteristics, advantages, limitations, and areas of application of the currently available in vivo and in vitro models of HBV infection.